The verdict
Our read at a glance.
Whether lypressin is understood as a historical, now-superseded vasopressin nasal spray for diabetes insipidus, rather than a current treatment.
- The signal
- Lypressin given as a nasal spray reduced excessive urination in central diabetes insipidus by supplying vasopressin's water-retaining action. But its effect was short, requiring frequent dosing, and desmopressin, longer-acting and with far less blood-pressure effect, largely replaced it.
- The unknown
- Little remains open; its role was settled by being superseded. Its interest now is historical, as the predecessor to desmopressin.
- Our read
- A superseded predecessor: lypressin was a workable early vasopressin nasal spray for diabetes insipidus, but its short action and pressor effect made it inferior to desmopressin, which replaced it. Read it as history, the first chapter of nasal vasopressin replacement, not a drug to use today.
The mechanism
How it works.
The body controls water through vasopressin (antidiuretic hormone), which tells the kidneys to hold onto water; in central diabetes insipidus the body makes too little, so people pass large volumes of dilute urine. Lypressin is a close variant of vasopressin (the lysine form found naturally in pigs) given as a nasal spray to replace that missing signal, switching on the kidney's water-conserving receptors. It works, but it is broken down quickly, so its effect is short and it needs frequent dosing, and it also nudges blood vessels to constrict. Desmopressin is a refined version that lasts much longer and acts almost only on the kidney's water receptors, which is why it replaced lypressin.
Safety & regulatory boundary
The consequential part.
Lypressin's effects were those of vasopressin, mainly water retention, with some blood-vessel (pressor) effect and nasal irritation from the spray. It is a historical product, largely discontinued, and not a current treatment for diabetes insipidus, where desmopressin is now standard. It should be read as the earlier, short-acting predecessor, not an available option.
What's next
What we're watching.
Nothing active; lypressin's relevance is historical, as the short-acting predecessor that desmopressin replaced.
Context
Why this is discussed.
Lypressin is a piece of the diabetes-insipidus story: an early vasopressin nasal spray that let people replace the missing water-conserving hormone, before the better, longer-lasting desmopressin took over. It shows how a workable first drug gets superseded by a refined successor.
The evidence base
7 cited references.
Indexed literature (PubMed)7
Glavaš M et al. · Int J Mol Sci · 2022
EISENBERG E · Calif Med · 1965
CHIRMAN SB et al. · Calif Med · 1964
Kochar MS · Am J Kidney Dis · 1985
Kam PC et al. · Anaesthesia · 2004
Skopková J et al. · Endocrinol Exp · 1981
Shucart WA et al. · J Neurosurg · 1976
Keep reading